(Q38090812)

28 August 2017

0 references

Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens (English)

1 reference

28 August 2017

1 reference

1

Fred Saad

1 reference

28 August 2017

Kurt Miller

2

1 reference

28 August 2017

publication date

15 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

32

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

70-79

1 reference

28 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Castration-resistant prostate cancer: systemic therapy in 2012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Docetaxel-based combination therapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Guidelines for the management of castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Emerging novel therapies for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Microtubules and resistance to tubulin-binding agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Abiraterone in metastatic prostate cancer without previous chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Abiraterone and increased survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Increased survival with enzalutamide in prostate cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Identification of docetaxel resistance genes in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Chemotherapy-based treatment for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Drug resistance in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Novel therapies for metastatic castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Role of tyrosine kinase inhibitors in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

The role of Src in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-Fms and diverts the cells to dendritic cell lineage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Src kinase activity is essential for osteoclast function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Decreased c-Src expression enhances osteoblast differentiation and bone formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Regulation of androgen receptor activity by tyrosine phosphorylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Emerging targeted therapies for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.01.005

10.1016/J.UROLONC.2013.01.005

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference